SCHEMBL3532997

SCHEMBL3532997

O=S(=O)(c1ccccc1)c1n[nH]c2c(OCCN3CCCCC3)cccc12

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 3/20 0.53
TSHR P16473 1/20 0.45
KDM4E B2RXH2 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
HRH1 P35367 3/20 0.45
DRD1 P21728 3/20 0.45
DRD3 P35462 3/20 0.45
DRD2 P14416 2/20 0.45
DRD4 P21917 2/20 0.45
DRD5 P21918 2/20 0.45
HRH3 Q9Y5N1 4/20 0.44
HTR2A P28223 2/20 0.44
HTR7 P34969 2/20 0.44
TDP1 Q9NUW8 2/20 0.43
MEN1 O00255 1/20 0.43
GAA P10253 1/20 0.43
KMT2A Q03164 1/20 0.43
ABCB1 P08183 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3530152 0.99 HTR6 (0.54) HTR6TSHRKDM4ESMN1; SMN2HRH1
SCHEMBL3535542 0.88 HTR6 (0.48) HTR6TSHRHRH3HTR2AHTR7
SCHEMBL3531145 0.87 HTR6 (0.48) HTR6HRH3HTR2AHTR7TDP1
SCHEMBL3533205 0.82 HTR1B (0.43) HTR6KDM4ESMN1; SMN2ABCB1
SCHEMBL3535808 0.79 HTR6 (0.48) HTR6KDM4EHRH1DRD3DRD2
SCHEMBL3534079 0.78 HTR1B (0.43) HTR6KDM4ESMN1; SMN2DRD1DRD3
SCHEMBL3321950 0.78 HTR6 (0.81) HTR6HRH1DRD1DRD3DRD2
SCHEMBL3535864 0.78 GAK (0.48) DRD2HRH3
SCHEMBL3528627 0.77 TDP1 (0.47) HTR6TSHRKDM4ESMN1; SMN2HRH1
Hydrochloric Acid SCHEMBL5242993 0.77 HTR6 (0.80) HTR6HRH1DRD1DRD3DRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070037802-A1 such as N,N-Dimethyl-3-{[3-(1-naphthylsulfonyl)-1H-indazol-5-yl]oxy}propan-1-amine, used for the treatment of a central nervous system disorders WYETH (US) 2007-02-15 US claimed
US-7723329-B2 Substituted-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6 ligands WYETH LLC (US) 2010-05-25 US disclosed
US-20070037802-A1 such as N,N-Dimethyl-3-{[3-(1-naphthylsulfonyl)-1H-indazol-5-yl]oxy}propan-1-amine, used for the treatment of a central nervous system disorders WYETH (US) 2007-02-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070037802-A1 such as N,N-Dimethyl-3-{[3-(1-naphthylsulfonyl)-1H-indazol-5-yl]oxy}propan-1-amine, used for the treatment of a central nervous system disorders HTR6, TPH1, HTR1A HTR6 1/4885TSHR 453/4885KDM4E 3348/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.